drugset
drugset / Trial / NCT01100684

Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)

NCT01100684 ↗

Phase 3 Completed 611 enrolled Tioga Pharmaceuticals RTI Health Solutions · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether asimadoline is safe and effective at treating D-IBS.

Timeline

Start
2010-05
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Asimadoline Small molecule 0.5 mg —

Indications

irritable bowel syndrome